Nontapering versus tapering prednisone in acute exacerbations of asthma: a pilot trial.
Controversy exists as to whether or not the dose of prednisone should be tapered in patients discharged from the emergency department after initial treatment for an acute exacerbation of asthma. We assessed the rates of relapse and rebound in a group of 28 patients treated with a nontapering course of prednisone and compared their outcomes to an historical control group of 48 patients treated with a typical tapering course of prednisone. We found no significant difference in the rates of relapse or rebound between the nontapering dose patients and the tapering dose patients within either 21 days of discharge or within 10 days after stopping prednisone. Fifty-four percent of study patients reported adverse effects that could be attributed to prednisone. Our preliminary findings suggest that tapering of prednisone may not be needed in these patients.
Verbeek
P R
PR
Division of Emergency Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
Geerts
W H
WH
D000208:Acute Disease; D000328:Adult; D000359:Aftercare; D001249:Asthma / Q000188:drug therapy*; D016009:Chi-Square Distribution; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence
D005938:Glucocorticoids; D011241:Prednisone